FibroBiologics, Inc. Cash and Restricted Cash
FibroBiologics, Inc. (FBLG) had Cash and Restricted Cash of $3.52 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-31
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.52M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $3.52M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $1.48M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $4.89M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $4.87M 10-Q · filed 2025-10-31 |
| 2025-06-30 | $8.85M 10-Q · filed 2026-07-31 |
| 2025-03-31 | $8.67M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $13.98M 10-Q · filed 2026-07-31 |
| 2024-09-30 | $7.83M 10-Q · filed 2025-10-31 |
| 2024-06-30 | $5.97M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $8.16M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $9.16M 10-K · filed 2026-02-24 |
| 2023-09-30 | $10.77M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $11.38M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $14.74M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $2.27M 10-K · filed 2025-03-31 |
| 2021-12-31 | $407.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |